Combination drug therapy for relapsed neuroblastoma
Part of Cancer clinical trials.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a type of nerve cancer called neuroblastoma that has come back or is not getting better with treatment.
- They must be well enough to be active at least half the day (play, walk, or do daily tasks with help).
- Blood cell counts, kidney, liver, and heart function must be at safe levels (a doctor will check these).
- No serious infections, recent major surgeries, or severe nerve problems (like hearing loss or numbness).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
This trial tests adding the antibody dinutuximab-beta to standard chemotherapy for children and young adults with newly diagnosed high-risk neuroblastoma. The goal is to see if this combination helps the immune system fight the cancer better.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
Hear when a new Neuroblastoma (NB) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.